Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

STOCKHOLM, March 2, 2021 /PRNewswire/ -- Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical...

Read more: Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer...

More Articles …

  1. Marriott International Pilots AI Solutions to Streamline Hotel Design Process for Future Properties in Asia-Pacific
  2. LCM Partners wins two Private Debt Investor 2020 awards
  3. INEOS Styrolution's Zylar 261 used in Samsung's new range of household appliances
  4. Tezos Baking enables Sylo Smart Wallet users to earn rewards from holding XTZ
  5. Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
  6. Nintex Workflow Cloud Helps Zoom Improve Channel Order Process
  7. K7 Computing Launches Lifetime Valid Antivirus - K7 Ultimate Security Infiniti Edition
  8. CORE to open an Australian office to assist Australian entrepreneurs looking to start a business in Hong Kong
  9. TVM Capital Healthcare Exits Cambridge Medical and Rehabilitation Center for US$ 232 Million, a 4.6x Return on Capital Invested
  10. Atradius Collections expands its global presence with the acquisition of Gestifatura